P131 Phase I trial of the combination of the epigenetic modulators vorinostat and azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). An update from the NY Cancer Consortium

L. Silverman, A. Verma, R. Odchimar-Reissig, A. LeBlane, V. Najfeld, J. Gabrilove, L. Isola, I. Espinoza-Delgado, J. Zwiebel

Research output: Contribution to journalArticlepeer-review

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)S135-S136
JournalLeukemia Research
Issue numberSUPPL. 1
StatePublished - May 2009
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this